Cargando…

The Value of Rotavirus Vaccination in Europe: A Call for Action

ABSTRACT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has pushed many healthcare systems into crisis. High vaccine coverage amongst children reduces emergency room presentations, hospital admissions and deaths due to vaccine-preventable diseases, freeing up healthcare r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Robert, Martinón-Torres, Federico, Posiuniene, Inga, Benninghoff, Bernd, Oh, Kyu-Bin, Poelaert, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647247/
https://www.ncbi.nlm.nih.gov/pubmed/36355309
http://dx.doi.org/10.1007/s40121-022-00697-7
_version_ 1784827346222579712
author Cohen, Robert
Martinón-Torres, Federico
Posiuniene, Inga
Benninghoff, Bernd
Oh, Kyu-Bin
Poelaert, Dirk
author_facet Cohen, Robert
Martinón-Torres, Federico
Posiuniene, Inga
Benninghoff, Bernd
Oh, Kyu-Bin
Poelaert, Dirk
author_sort Cohen, Robert
collection PubMed
description ABSTRACT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has pushed many healthcare systems into crisis. High vaccine coverage amongst children reduces emergency room presentations, hospital admissions and deaths due to vaccine-preventable diseases, freeing up healthcare resources including polymerase chain reaction testing for patients with SARS-CoV-2. In Europe, rotavirus gastroenteritis leads to 75,000–150,000 hospitalisations and up to 600,000 medical encounters annually. Nevertheless, in 2022, only 18 countries in Europe (out of 38) have a publicly funded routine universal mass immunisation programme against rotavirus gastroenteritis. Evidence available in the last few years re-emphasises that rotavirus vaccines currently available in Europe are highly effective, preventing up to 96% of rotavirus-related hospitalisations in children less than 1 year of age (potentially 72,000–144,000 hospitalisations Europe-wide). Long-term surveillance indicates that rotavirus vaccination does not result in an overall increase in intussusception. On the contrary, increasing evidence suggests an overall reduction in intussusception in the first 12 months of life when early, high rotavirus vaccine coverage is achieved. Prevention of rotavirus gastroenteritis has marked positive impacts on parental wages and government tax revenue, with benefits extending across the whole economy. In the SARS-CoV-2 pandemic setting there is a new imperative to achieve high levels of paediatric vaccination against vaccine-preventable diseases, including rotavirus gastroenteritis. The introduction of rotavirus universal mass vaccination can be expected to reduce the number of preventable illnesses, hospitalisations and deaths caused by rotavirus gastroenteritis. Reducing vaccine-preventable diseases is particularly urgent at this time when healthcare systems are preoccupied and overwhelmed with SARS-CoV-2. Graphical abstract available for this article. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9647247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-96472472022-11-14 The Value of Rotavirus Vaccination in Europe: A Call for Action Cohen, Robert Martinón-Torres, Federico Posiuniene, Inga Benninghoff, Bernd Oh, Kyu-Bin Poelaert, Dirk Infect Dis Ther Commentary ABSTRACT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has pushed many healthcare systems into crisis. High vaccine coverage amongst children reduces emergency room presentations, hospital admissions and deaths due to vaccine-preventable diseases, freeing up healthcare resources including polymerase chain reaction testing for patients with SARS-CoV-2. In Europe, rotavirus gastroenteritis leads to 75,000–150,000 hospitalisations and up to 600,000 medical encounters annually. Nevertheless, in 2022, only 18 countries in Europe (out of 38) have a publicly funded routine universal mass immunisation programme against rotavirus gastroenteritis. Evidence available in the last few years re-emphasises that rotavirus vaccines currently available in Europe are highly effective, preventing up to 96% of rotavirus-related hospitalisations in children less than 1 year of age (potentially 72,000–144,000 hospitalisations Europe-wide). Long-term surveillance indicates that rotavirus vaccination does not result in an overall increase in intussusception. On the contrary, increasing evidence suggests an overall reduction in intussusception in the first 12 months of life when early, high rotavirus vaccine coverage is achieved. Prevention of rotavirus gastroenteritis has marked positive impacts on parental wages and government tax revenue, with benefits extending across the whole economy. In the SARS-CoV-2 pandemic setting there is a new imperative to achieve high levels of paediatric vaccination against vaccine-preventable diseases, including rotavirus gastroenteritis. The introduction of rotavirus universal mass vaccination can be expected to reduce the number of preventable illnesses, hospitalisations and deaths caused by rotavirus gastroenteritis. Reducing vaccine-preventable diseases is particularly urgent at this time when healthcare systems are preoccupied and overwhelmed with SARS-CoV-2. Graphical abstract available for this article. GRAPHICAL ABSTRACT: [Image: see text] Springer Healthcare 2022-11-10 2023-01 /pmc/articles/PMC9647247/ /pubmed/36355309 http://dx.doi.org/10.1007/s40121-022-00697-7 Text en © GSK 2022 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Cohen, Robert
Martinón-Torres, Federico
Posiuniene, Inga
Benninghoff, Bernd
Oh, Kyu-Bin
Poelaert, Dirk
The Value of Rotavirus Vaccination in Europe: A Call for Action
title The Value of Rotavirus Vaccination in Europe: A Call for Action
title_full The Value of Rotavirus Vaccination in Europe: A Call for Action
title_fullStr The Value of Rotavirus Vaccination in Europe: A Call for Action
title_full_unstemmed The Value of Rotavirus Vaccination in Europe: A Call for Action
title_short The Value of Rotavirus Vaccination in Europe: A Call for Action
title_sort value of rotavirus vaccination in europe: a call for action
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647247/
https://www.ncbi.nlm.nih.gov/pubmed/36355309
http://dx.doi.org/10.1007/s40121-022-00697-7
work_keys_str_mv AT cohenrobert thevalueofrotavirusvaccinationineuropeacallforaction
AT martinontorresfederico thevalueofrotavirusvaccinationineuropeacallforaction
AT posiunieneinga thevalueofrotavirusvaccinationineuropeacallforaction
AT benninghoffbernd thevalueofrotavirusvaccinationineuropeacallforaction
AT ohkyubin thevalueofrotavirusvaccinationineuropeacallforaction
AT poelaertdirk thevalueofrotavirusvaccinationineuropeacallforaction
AT cohenrobert valueofrotavirusvaccinationineuropeacallforaction
AT martinontorresfederico valueofrotavirusvaccinationineuropeacallforaction
AT posiunieneinga valueofrotavirusvaccinationineuropeacallforaction
AT benninghoffbernd valueofrotavirusvaccinationineuropeacallforaction
AT ohkyubin valueofrotavirusvaccinationineuropeacallforaction
AT poelaertdirk valueofrotavirusvaccinationineuropeacallforaction